Cinctive Capital Management LP Sells 5,694 Shares of argenex SE $ARGX

Cinctive Capital Management LP cut its position in shares of argenex SE (NASDAQ:ARGX) by 46.3% in the fourth quarter, HoldingsChannel reports. The firm owned 6,606 shares of the company’s stock after selling 5,694 shares during the period. Cinctive Capital Management LP’s holdings in argenex were worth $5,555,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of ARGX. American Century Companies Inc. increased its holdings in shares of argenex by 11.6% in the 3rd quarter. American Century Companies Inc. now owns 229,770 shares of the company’s stock valued at $169,474,000 after acquiring an additional 23,864 shares during the period. US Bancorp DE increased its holdings in shares of argenex by 37.2% in the 3rd quarter. US Bancorp DE now owns 7,073 shares of the company’s stock valued at $5,217,000 after acquiring an additional 1,919 shares during the period. Sands Capital Management LLC purchased a new position in shares of argenex in the 3rd quarter valued at $12,262,000. Assenagon Asset Management S.A. purchased a new position in shares of argenex in the 4th quarter valued at $20,475,000. Finally, Fiera Capital Corp increased its holdings in shares of argenex by 12.1% in the 3rd quarter. Fiera Capital Corp now owns 177,654 shares of the company’s stock valued at $131,030,000 after acquiring an additional 19,180 shares during the period. 60.32% of the stock is owned by institutional investors.

argenex Stock Performance

Shares of ARGX opened at $892.26 on Thursday. The stock has a 50-day moving average of $820.36 and a two-hundred day moving average of $810.81. argenex SE has a one year low of $510.05 and a one year high of $934.62. The stock has a market cap of $55.49 billion, a P/E ratio of 39.73, a P/E/G ratio of 1.34 and a beta of 0.47.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The company had revenue of $1.31 billion during the quarter. Analysts predict that argenex SE will post 26.19 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ARGX. Guggenheim lifted their price target on argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a report on Friday, May 8th. Oppenheimer cut their price target on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research note on Monday, April 20th. Robert W. Baird boosted their target price on argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. Finally, Wall Street Zen downgraded argenex from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,019.50.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.